Jonathan Hanley
Profile
Jonathan Hanley worked as a Director of Functional Proteomics at GenOdyssee SA, Manager of Research & Development Alliance at Génomic Vision SA, Head of Biotechnology at National Physical Laboratory Ltd., and Analyst at Société Générale Asset Mgmt Alternative Invt (Private Equity).
He holds a Doctorate from University College London, an MBA from Ecole Nationale des Ponts et Chaussées, and an undergraduate degree from the University of Portsmouth.
Former positions of Jonathan Hanley
Companies | Position | End |
---|---|---|
Société Générale Asset Mgmt Alternative Invt (Private Equity)
Société Générale Asset Mgmt Alternative Invt (Private Equity) Investment ManagersFinance Societé Générale Asset Management Alternative Investment/Private Equity (SGAM AI/PE) is the banking group's European asset management center for Private Equity. They are located in Paris-La Défense. SGAM AI/PE is a division of the Société Générale Asset Management, established in 2003, which is a subsidiary of the bank's Global Investment Management and Services division. The ultimate parent firm is the French financial institution Société Générale (PK: SCGLY), established in 1864. Nationalized at different intervals throughout their history, the bank is in the private sector since 1997. SGAM AI/PE is composed of three units: venture capital, expansion capital and buyout, and fund of funds. In addition to their Paris office, they are also present in London, Milan, Munich, Warsaw, Bucharest and Casablanca. | Private Equity Analyst | 15/02/2010 |
National Physical Laboratory Ltd.
National Physical Laboratory Ltd. Miscellaneous Commercial ServicesCommercial Services National Physical Laboratory Ltd. operates as a research institute focused on developing and applying measurement standards, science, and technology. The private company is based in Teddington, UK, and has subsidiaries in the United Kingdom. | Corporate Officer/Principal | - |
GenOdyssee SA
GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | Corporate Officer/Principal | - |
GENOMIC VISION | Corporate Officer/Principal | - |
Training of Jonathan Hanley
University of Portsmouth | Undergraduate Degree |
University College London | Doctorate Degree |
Ecole Nationale des Ponts et Chaussées | Masters Business Admin |
Experiences
Positions held
Linked companies
Listed companies | 1 |
---|---|
GENOMIC VISION | Health Technology |
Private companies | 3 |
---|---|
Société Générale Asset Mgmt Alternative Invt (Private Equity)
Société Générale Asset Mgmt Alternative Invt (Private Equity) Investment ManagersFinance Societé Générale Asset Management Alternative Investment/Private Equity (SGAM AI/PE) is the banking group's European asset management center for Private Equity. They are located in Paris-La Défense. SGAM AI/PE is a division of the Société Générale Asset Management, established in 2003, which is a subsidiary of the bank's Global Investment Management and Services division. The ultimate parent firm is the French financial institution Société Générale (PK: SCGLY), established in 1864. Nationalized at different intervals throughout their history, the bank is in the private sector since 1997. SGAM AI/PE is composed of three units: venture capital, expansion capital and buyout, and fund of funds. In addition to their Paris office, they are also present in London, Milan, Munich, Warsaw, Bucharest and Casablanca. | Finance |
GenOdyssee SA
GenOdyssee SA Miscellaneous Commercial ServicesCommercial Services GenOdyssee is a drug discovery company using a unique, IP-protected approach to discovery of superior protein products. GenOdyssee discovers natural variants of proteins with higher efficacy and safety than marketed versions of the same therapeutic proteins. This approach is ideal for discovery of 'next generation' protein products for already developed blockbuster markets. The company has a proprietary genomic DNA databank representative of the human population, which is screened for natural genetic variants of therapeutic proteins with superior properties. This approach to drug discovery is based on the idea that natural evolution may have lead to the generation in the current population of unpredictable mutations that would confer superior therapeutic status to known human therapeutic proteins. | Commercial Services |
National Physical Laboratory Ltd.
National Physical Laboratory Ltd. Miscellaneous Commercial ServicesCommercial Services National Physical Laboratory Ltd. operates as a research institute focused on developing and applying measurement standards, science, and technology. The private company is based in Teddington, UK, and has subsidiaries in the United Kingdom. | Commercial Services |
- Stock Market
- Insiders
- Jonathan Hanley